



Association of Non-Alcoholic Fatty Liver Disease with Increased Carotid Intima-Media Thickness Considering Other Cardiovascular Risk Factors

Ali Mohammadzadeh¹, Vahid Shahkarami¹, Madjid Shakiba², Parto Sabetrasekh² and Maryam Mohammadzadeh^{3,*}

¹Department of Radiology, Rajaie Cardiovascular and Medical Research Center, Iran University of Medical Sciences, Tehran, Iran

²Advanced Diagnostic and Interventional Radiology Research Center, Tehran University of Medical Sciences, Tehran, Iran

³Department of Radiology, Amiralam Hospital, Tehran University of Medical Sciences, Tehran, Iran

*Corresponding author: Department of Radiology, Amiralam Hospital, Tehran University of Medical Sciences, Tehran, Iran. Email: mmm1361@yahoo.com

Received 2017 May 29; Revised 2019 March 19; Accepted 2019 March 17.

Abstract

Background: Non-alcoholic fatty liver disease (NAFLD) is the most common liver disease (6% - 35%) and is associated with cardiovascular risk factors and metabolic syndromes (age, diabetes, hyperlipidemia, hypertension and smoking). Hereby, we evaluated the association of increased carotid intima-media thickness (IMT) with NAFLD considering other cardiovascular risk factors to see if NAFLD is independently associated with increased carotid IMT.

Patients and Methods: Totally 300 patients [150 NAFLD and 150 normal] who were referred to four academic referral hospitals were enrolled. Patients with a history of alcohol use, hepatitis, HIV, chemotherapy and other organ failures were excluded. A single radiologist performed abdominal sonographies [3 - 5 MHz probe] and carotid sonography [7.5 MHz probe] (measured the posterior wall of both common carotids and calculated the mean value). NAFLD was diagnosed based on sonographic findings in the absence of acute or chronic liver and kidney diseases and malignancies.

Results: The mean age was 51.2 ± 14.8 [20 - 97] and 184 [61.3%] were male. Mean IMT was greater in patients with diabetes, hypertension, hyperlipidemia and NAFLD [all P s < 0.001] and these variables with age were statistically significant in univariate models for estimating IMT. Among NAFLD patients, 38 [25.3%] had increased IMT [unilateral or bilateral; considering 0.8 as cutoff point] while this frequency was 8 [5.3%] among normal subjects [P < 0.001, odds ratio = 6, 95% confidence interval (CI) = 2.7 - 13.4]. In multivariate regression models [IMT as dependent variable], NAFLD, age and hyperlipoproteinemia (HLP) were independent significant variables in linear model [$R^2 = 0.41$] and NAFLD showed highest odds ratio [16.4] among significant variables [age, body mass index (BMI), NAFLD and HLP] in the logistic model.

Conclusion: Increase carotid IMT is highly associated with NAFLD independent of other cardiovascular risk factors and should be considered in these patients.

Keywords: Sonography, Non-Alcoholic Fatty Liver Disease, Carotid Artery, Intima-Media Thickness

1. Background

Nowadays, non-alcoholic fatty liver disease (NAFLD) is a suffering problem in our population. The prevalence of this phenomenon raised from 2.9% - 3.3% in 2011 to 21.5% in 2013 probably due to change of lifestyle (reducing physical activity and bad dietary regimen) or the increase in capabilities of physicians or utility of diagnostic tools for disease screening (1, 2). Various risk factors have been identified in the pathogenesis of NAFLD including insulin resistance, stress oxidative, diabetes, hyperlipidemia, obesity, and metabolic syndrome (3-7). In recent decades, an

upward trend in the prevalence of obesity was found in all ages that among those, obesity has been suggested as the most important risk factor for NAFLD. This issue can highlight the importance of NAFLD as one of the important chronic liver diseases in the entire world (8-10). Now, NAFLD is known as a common debilitating disorder among adults as well as one of the most important causes for growth retardation in childhood (11).

NAFLD is revealed along with obesity, hyperlipidemia, cardiovascular diseases, and type II diabetes (12, 13). Hyperlipidemia can be revealed in about 20% to 80% of the affected patients (14). In a group of autopsied cases with

NAFLD, 20 out of 22 cases suffered from diabetes or hyperlipidemia (15). Additionally, about half of the hyperlipidemia patients may be diagnosed as NAFLD by sonography (16). Abdominal obesity, sudden weight loss, complete enteral nutrition, diverticulosis, medications and family history are main determinants of steatohepatitis.

The gold standard for diagnosing NAFLD is liver biopsy, while this approach is completely invasive leading to morbidity and even mortality (17). Besides, sonography is a reliable, available, and cost-benefit tool as compared to other modalities. Hence, in spite of its potential limitations, the researchers believe that sonography is the safest for screening NAFLD (18).

Pathophysiologically, NAFLD has a progressive nature with a degree of inflammation and fibrosis with a tendency to end-stage liver disease, cirrhosis or even hepatocellular carcinoma that result in poor prognosis and high mortality (19, 20). Thus, the importance of its early diagnosis and management is absolutely clear (21). Patients with NAFLD highly tend to suffer from atherosclerotic disorders manifested as increasing carotid intima-media thickness (IMT) or coronary atherosclerotic lesions (22-25). In other words, NAFLD patients are susceptible to liver disease-related death or life-threatening cardiovascular disorders (26-29).

Recent studies have attempted to assess the relation between fatty liver disease and atherosclerosis indicating this close link (30, 31). Some risk factors for coronary artery disease or carotid atherosclerosis can be commonly found in NAFLD. In this regard, simultaneously occurring NAFLD and atherosclerosis patterns can be shown in 2.3% to 54% of patients (32-34). Advanced age, female gender, hypertension, diabetes, and smoking potentially increase the likelihood for both coronary stenosis and carotid artery atherosclerosis (35, 36). In recent decades, the link between liver steatosis and carotid atherosclerosis has been also suggested. Although some studies could not find any association among increased c-IMT following NAFLD and its consequent cardiovascular disorders (37), some cross-sectional and case-control studies could show NAFLD and c-IMT as independent predictors for cardiovascular diseases and carotid atherosclerotic plaques (38-41). However, some other studies could not find this association (37). This contradictory result may be due to employing nonstandard diagnostic procedures or using linear probes with low-level frequency at sonography. Also, the studies on the increased risk for cardiovascular disorders in those with NAFLD led to paradoxical findings (42, 43). Additionally, some observations suggested that hypothyroidism may increase c-IMT (44), but it was not observed in other surveys (45). The

probable association between liver steatosis and carotid lesions may lead to poor clinical outcome requiring repeated annual sonographic assessments. In these cases, more assessment of carotid arteries may be indicated.

2. Objectives

The present study aimed to assess the relationship between NAFLD and increase risk for atherosclerosis.

3. Patients and Methods

This study was performed on all patients who were admitted to the radiology department of Rsoul-e-Akram, Firouzgar, Shahid Rajaei, or Shohada hospitals between 2014 and 2016. Overall, 300 patients were enrolled and categorized as the case group (NAFLD group) or control group. The exclusion criteria were history of alcohol use, positive hepatitis or HIV infection, undergoing chemotherapy, evidence of lesion or failure of other organs, pregnancy, or infancy. Anthropometric parameters were measured by a single trained nurse. Laboratory indices assessed in single reference laboratory included fasting blood sugar (FBS), triglyceride (TG), total cholesterol (TC), low density lipoprotein (LDL), and body mass index (BMI). All data were set at the study checklist. Abdominal sonography was conducted using a probe 3 to 5 MHz and carotid sonography using a probe 7.5 MHz by a single sonographer. The subjects who were diagnosed as grade I NAFLD had all criteria of disease and therefore, those with marginal or borderline patterns were not considered as our cases. NAFLD was diagnosed based on the diagnostic criteria including sonographic findings in the absence of cardiovascular disorders, acute or chronic liver diseases, malignancies, acute or chronic renal diseases, history of alcohol use (higher than 40 g/day for men and 20 g/day for women for more than 5 years), pregnancy, liver masses, abnormal Cu metabolism, or using drugs that adversely affected liver function. After liver assessment, the carotid IMT was assessed by sonography in all participants. According to the standard protocol, the posterior wall of both common carotids was assessed. The cutoff value of ≥ 0.8 mm was considered for increased c-IMT (37) although a reference range from 0.64 to 1.2 has been used as significant carotid thickness (Figures 1-3) (22, 28).

Results were presented as mean \pm standard deviation (SD) for quantitative variables and were summarized by absolute frequencies and percentages for categorical variables. Normality of data was analyzed using the Kolmogorov-Smirnov test. Categorical variables were




Figure 1. Intima media thickness (IMT) measurement - B-mode ultrasonography. IMT is measured as the distance between calipers (lumen-intima interface) shown with the white arrows. High-resolution B-mode system equipped with a linear array transducer > 7 MHz with minimal compression at a distance of at least 5 mm below the distal end of common carotid artery (CCA) with averaging of three measurements. A, A 50-year-old female with flank pain. White arrow show thin IMT. B, A 40-year-old female with hyperlipidemia as the incidental finding during checkup. White arrow shows medium IMT. C, A 62-year-old male with a medical history of atherosclerosis, coronary artery disease and fatty liver. White arrow shows thick IMT.

compared using chi-square test or Fisher's exact test when more than 20% of cells with an expected count of less than five were observed. Quantitative variables were also compared with t test, NOVA test, Mann-Whitney U test, or Kruskal-Wallis test. For statistical analysis, statistical software SPSS version 16.0 for windows (SPSS Inc., Chicago, IL) was used. P values of 0.05 or less were considered statistically significant.

4. Results

Among 300 subjects enrolled in the study, 150 had NAFLD [50%]; in which, 118 were grade 1 [%78.7], 28 were grade 2 [%18.7] and four were grade 3 [%2.7]. The mean age

of NAFLD patients and normal subjects were 49.9 ± 13.2 [20 - 80] and 52.5 ± 16.2 [21 - 97] [$P = 0.12$]. Among the NAFLD group, 98 [%65.3] were male while in normal subjects, 86 [%57.3] were male [$P = 0.16$]. The mean weight of NAFLD patients and normal subjects were 82 ± 13.1 and 77.5 ± 15.3 [$P = 0.007$]. Mean BMI of NAFLD patients and normal subjects were 29.1 ± 4.5 and 28.1 ± 5 [$P = 0.069$]. Among all subjects, 78 [%26] had hyperlipidemia, 71 [%23.7] had hypertension, 41 [%13.7] were smokers and 61 [%20.3] were diabetic or showed impaired glucose tolerance test (IGTT) (45 were diabetic [%15] and 16 showed IGTT [%5.3]). Mean right and left IMTs were 0.56 ± 0.18 [0.25 - 1.5] and 0.57 ± 0.18 [0.25 - 1.45] respectively [$P = 0.026$]. Considering a cutoff point of ≥ 0.8 as increased IMT, we had 37 [%12.3] and 38 [%12.7] patients



Figure 2. Normal liver (grade 0). A 35-year-old male with no underlying disease. He underwent abdominal B-mode ultrasonography for vague abdominal pain. Solid two-way arrow: almost same echogenicity of liver and kidney; open arrows: portal and ductal wall echogenicity.



Figure 3. Fatty liver (grade 2) - B-mode ultrasonography. A 47-year-old female, 70kg with mild hypertension and slightly abnormal liver function tests (LFT). Moderate increased liver echo. The solid arrow shows obscured portal wall echogenicity and the open arrow shows focal fat sparing.

with increased IMT on right and left sides respectively. Totally, we had 46 [%15.3] patients with at least one side increased IMT. Twenty nine patients had bilateral increased IMT [%9.7]. Association of cardiovascular risk factors with NAFLD was statistically nonsignificant while the mean of IMT among patients with these risk factors were higher than patients without them. The findings have been mentioned in [Table 1](#).

Mean age of patients in increased IMT patients versus others were 61.8 ± 11.2 and 49.3 ± 14.6 , respectively [$P < 0.001$]. Mean BMI of patients in increased IMT patients versus others were 27 ± 3.5 and 28.8 ± 4.9 , respectively [$P = 0.02$].

When we considered patients in three groups of no NAFLD, grade 1 NAFLD and grade (2 and 3) of NAFLD together, there was no association between smoking, hyper-

Table 1. Association of HTN, HLP, Diabetes and Smoking with NAFLD and IMT

	NAFLD		IMT	
	No. (%)	P value	Mean ± SD	P value
HTN		0.89		< 0.001
Yes	35 (49.3)		0.64 ± 0.16	
No	115 (50.2)		0.54 ± 0.17	
HLP		0.6		< 0.001
Yes	37 (47.4)		0.66 ± 0.21	
No	113 (50.9)		0.53 ± 0.15	
Smoking		0.24		0.12
Yes	24 (58.5)		0.59 ± 0.15	
No	126 (48.6)		0.56 ± 0.18	
Diabetes or IGT		0.89		< 0.001
Yes	30 (49.2)		0.65 ± 0.18	
No	20 (50.2)		0.54 ± 0.17	
NAFLD				< 0.001
Yes	-		0.62 ± 0.19	
No	-		0.5 ± 0.13	

Abbreviations: HLP, hyperlipoproteinemia; HTN, hypertension; IGGT, impaired glucose tolerance test; IMT, intima-media thickness; NAFLD, non-alcoholic fatty liver disease; SD, standard deviation

tension (HTN), diabetes and hyperlipoproteinemia (HLP) with this new classification [all P-values > 0.1]. Mean IMT in grade 1 NAFLD patients was 0.62 ± 0.18 and it was 0.63 ± 0.22 in group 2 and 3 NAFLD patients [P > 0.9]. Among NAFLD patients, 38 had increased IMT [uni- or bilateral] [%25.3] while this frequency was 8 [%5.3] among normal subjects [P < 0.001, odds ratio = 6, 95% confidence interval = 2.7 - 13.4]. Mean IMT in men and women were 0.57 ± 0.19 and 0.55 ± 0.15 [P = 0.32].

Among diabetic patients, 18 [%29.5] showed increased IMT while among others, 28 [%11.7] had increased IMT [P = 0.001, odds ratio = 3.2, 95% confidence interval = 1.6 - 6.2]. Among HLP patients, 22 [%28.2] showed increased IMT while among others, 24 [%10.8] had increased IMT [P < 0.001, odds ratio = 3.2, 95% confidence interval = 1.7 - 6.2]. Among HTN patients, 17 [%23.9] showed increased IMT while among others, 29 [%12.7] had increased IMT [P = 0.02, odds ratio = 2.2, 95% confidence interval = 1.1 - 4.2]. Among smokers, five [%12.2] showed increased IMT while among others, 41 [%15.8] had increased IMT [P = 0.55].

We calculated univariate regression models considering IMT as dependent variable and age, BMI, smoking, HLP, diabetes and HTN as independent variables [These models were constructed in NAFLD patients, normal subjects and all subjects separately]. In this relation, we calculated linear regression models [when we considered the exact value

of IMT measured by sonography] and logistic regression models [when we considered a dichotomous variable for IMT determined by mentioned cutoff point of ≥ 0.8] separately (Table 2).

Considering statistically significant univariate linear and logistic regression models [age, HLP, HTN, diabetes and NAFLD in linear regression and age, BMI, HLP, HTN, diabetes and NAFLD in logistic regression], we calculated multivariate regression model considering IMT as a dependent variable. Results showed an adjusted R square of 0.41 for the linear regression model and R square of 0.24 in logistic regression model. Age, NAFLD, and HLP were significant independent variables in the linear model and age, NAFLD, BMI and HLP were significant independent variables in the logistic model (Table 3).

5. Discussion

NAFLD is a feature of liver esteatosis with or without inflammation or fibrosis (46). It is the most common liver disorder in western countries (47). Moreover, the high prevalence of atherosclerosis in such patients encouraged us to assess the sonographic value of c-IMT in those patients with NAFLD (48). In other words, it is unknown whether NAFLD can predict an increased risk for cardiovascular atherosclerotic disorders especially in initial phases

Table 2. Univariate Linear and Logistic Regression Models Considering IMT as a Dependent Variable in All Patients and NAFLD and Normal Groups Separately

Independent variable	Linear regression			Logistic regression			
	Adjusted R square	Coefficient	P value	R square	Odds ratio	%95 CI	P value
Age							
All	0.22	0.006	< 0.001	0.09	1.06	1.03 - 1.09	< 0.001
NAFLD	0.3	0.008	< 0.001	0.02	1.11	1.06 - 1.15	< 0.001
No NAFLD	0.33	0.005	< 0.001	0.06	1.08	1.02 - 1.14	0.01
BMI							
All	-0.002	-0.001	0.52	0.02	0.91	0.85 - 0.99	0.02
NAFLD	0.1	-0.005	0.12	0.04	0.9	0.81 - 0.99	0.02
No NAFLD	-0.006	-0.001	0.77	0.04	0.79	0.65 - 0.98	0.03
HLP							
All	0.1	0.13	< 0.001	0.04	3.2	1.7 - 6.2	< 0.001
NAFLD	0.16	0.18	< 0.001	0.08	4.4	2 - 9.9	< 0.001
No NAFLD	0.07	0.08	< 0.001	0.01	2.8	0.68 - 11.9	0.15
HTN							
All	0.06	0.11	< 0.001	0.02	2.2	1.1 - 4.2	0.02
NAFLD	0.05	0.1	0.005	0.01	1.8	0.78 - 4.1	0.17
No NAFLD	0.12	0.11	< 0.001	0.04	6	1.4 - 26.4	0.02
Smoking							
All	0.001	0.03	0.28	0.001	0.74	0.27 - 2	0.55
NAFLD	0.001	-0.05	0.29	0.02	0.4	0.1 - 1.3	0.13
No NAFLD	0.06	0.11	0.002	0.01	2.8	0.52 - 15.3	0.23
Diabetes							
All	0.06	0.11	< 0.001	0.035	3.2	1.6 - 6.2	0.001
NAFLD	0.09	0.14	< 0.001	0.07	4.2	1.8 - 9.8	0.001
No NAFLD	0.06	0.06	0.002	0.01	2.4	0.6 - 10.8	0.24
NAFLD	0.13	0.13	< 0.001	0.08	6	2.7 - 13.4	< 0.001

Abbreviations: BMI, body mass index; CI, confidence interval; HLP, hyperlipoproteinemia; HTN, hypertension; IMT, intima-media thickness; NAFLD, non-alcoholic fatty liver disease

(49). We first detected no association between BMI and c-IMT that was similar to the findings of Tarantino et al. (50), Chen et al. (31), and Sert et al. (51) studies. Nevertheless, the result of the study conducted by Jarvisalo et al. (52) Manco et al. (53) and Berenson et al. (54) was contrary to our observation because of their focus on children. This contradictory result might be due to the definition of metabolic syndrome in adulthood. Another result in our survey was not observing an association between c-IMT and gender.

We also revealed a direct association between age and c-IMT that was similar to studies carried out by Jarvisalo et al. (52), Berenson et al. (54). We also found an association between the change in lipid profiles and the value of c-IMT that was contrary to other studies (52, 53).

As other findings, hypertensive patients were found to have a higher value of c-IMT than normotensive ones. Regarding the association between the presence of diabetes and increased measure of c-IMT, this association was only found in the control group not in the case group similar to some previous studies (34, 43). This contradictory result can be due to the abnormal distribution of cases in the NAFLD group.

As the most important result, we showed an association between the presence of NAFLD and increase value of c-IMT that was similar to other studies (36, 55-62).

In addition, in this context, Akin et al. (62) could not also find difference in diabetic status between those with and without NAFLD (Figures 2 - 4).

Table 3. Multivariate Linear and Logistic Regression Models Between Significant Univariate Regressors of IMT as a Dependent Variable

Variable	Linear regression				Logistic regression		
	Unstandardized coefficients (B)	Standard error	Standardized coefficients (beta)	P value	Odds ratio	%95 CI	P value
NAFLD	0.14	0.02	0.41	< 0.001	16.4	5.9 - 45	< 0.001
Age	0.01	0.001	0.43	< 0.001	1.08	1.05 - 1.12	< 0.001
BMI	-	-	-	-	0.86	0.78 - 0.95	0.003
HLP	0.07	0.02	0.18	< 0.001	2.74	1.1 - 6.9	0.03
HTN	0.01	0.02	0.03	0.001	1.2	0.47 - 2.9	0.74
Diabetes	0.01	0.02	0.02	0.50	1.2	0.45 - 3.1	0.74
Constant	0.21	0.03	-	0.74	0.013	-	0.015

Abbreviations: BMI, body mass index; CI, confidence interval; HLP, hyperlipoproteinemia; HTN, hypertension; IMT, intima-media thickness; NAFLD, non-alcoholic fatty liver disease




Figure 4. Grades of fatty liver. A, A 24-year-old male with a fatty liver grade 0 (normal liver parenchyma and echogenicity). B, A 38-year-old female with fatty liver grade 1 (mild). The echogenicity is slightly increased with normal visualization of the diaphragm and the intrahepatic vessel borders. C, A 47-year-old female, 70 kg with mild hypertension and slightly abnormal liver function tests (LFT). Fatty liver grade 2 (moderate). The echogenicity is moderately increased, with slightly impaired visualization of the diaphragm or intrahepatic vessels. D, A 45-year-old male, 110 kg with no underlying disease but slightly abnormal LFT. Fatty liver grade 3 (severe). The echogenicity is markedly increased with poor visualization of the diaphragm, the intrahepatic vessels, and the posterior portion of the right lobe.

At last, the relation between smoking and increased c-IMT was observed only in the control group, not in the NAFLD group. In fact, c-IMT value was not overall associated with smoking that was similarly found in a study conducted by Chavez-Tapia et al. (63) but contrary to a study

performed by Chen et al. (31). It seems that the effect of smoking on c-IMT may be mimicked by powerful predicting effects of other risk factors such as the presence of NAFLD.

More interestingly, the power of NAFLD to predict in-

creased c-IMT was the highest when compared to other two factors including age and lipid levels. However, we found no association between the value of IMT and grading of NAFLD similar to the study conducted by Tarantino et al. (50). In Framingham study published in 2015, a microvascular defect in carotid was the main manifestation in NAFLD patients. Insignificant association observed in our study might be due to the fact that most patients in our survey had a low grade of disease as well as the abnormal distribution of patients in our study.

In conclusion, in patients with NAFLD, advanced age and increased level of lipids along with hypertensive and diabetic states could predict increased c-IMT and thus could be helpful for predicting cardiovascular diseases. However, it can be noted that NAFLD may not be an independent factor for predicting cardiovascular prognosis. In final, further studies with the aim of assessing NAFLD as a predictive factor for cardiovascular disease prognosis are recommended.

Footnotes

Authors' Contributions: Vahid Shahkarami: data gathering, acquisition, ultrasound, and study design; Ali Mohammadzadeh: ultrasound operation; Madjid Shakiba: statistical analysis; Parto Sabetraskh: major scientific revision; Maryam Mohammadzadeh: scientific writing

Conflict of Interests: There is no conflict of interests to be declared in this publication for any of the mentioned authors and contributors. No conflicting financial or commercial interests in our article has affected the rights and welfare of human subjects at any level of research, including data gathering, collecting and evaluating patient information, and statistical analysis. None of the authors have declared any investment, ownership, advisory role and other remuneration or any financial relations to supporting companies.

Ethical Approval: This study was approved by the ethics committee of Rajaie Cardiovascular Medical and Research Center (code number: 2295).

Financial Disclosure: None declared.

Funding/Support: No funding support was applicable for this study.

Patients Consent: This study was approved by the ethics committee of Rajaie Cardiovascular Medical & Research Center (code number: 2295)

References

1. Rogha M, Najafi N, Azari A, Kaji M, Pourmoghaddas Z, Rajabi F, et al. Non-alcoholic steatohepatitis in a sample of Iranian adult pop-

- ulation: Age is a risk factor. *Int J Prev Med.* 2011;2(1):24-7. [PubMed: 21448401]. [PubMed Central: PMC3063465].
2. Sohrabpour A, Rezvan H, Amini-Kafabadi S, Dayhim M, Merat S, Pourshams A. Prevalence of Nonalcoholic Steatohepatitis in Iran: A Population based Study. *Middle East J Dig Dis.* 2010;2(1):14-9. [PubMed: 25197507]. [PubMed Central: PMC4154901].
3. Crabb DW, Galli A, Fischer M, You M. Molecular mechanisms of alcoholic fatty liver: role of peroxisome proliferator-activated receptor alpha. *Alcohol.* 2004;34(1):35-8. doi: 10.1016/j.alcohol.2004.07.005. [PubMed: 15670663].
4. Machado M, Cortez-Pinto H. Non-alcoholic steatohepatitis and metabolic syndrome. *Curr Opin Clin Nutr Metab Care.* 2006;9(5):637-42. doi: 10.1097/01.mco.0000241677.40170.17. [PubMed: 16912563].
5. Angelico F, Del Ben M, Conti R, Francioso S, Feole K, Maccioni D, et al. Non-alcoholic fatty liver syndrome: a hepatic consequence of common metabolic diseases. *J Gastroenterol Hepatol.* 2003;18(5):588-94. doi: 10.1046/j.1440-1746.2003.02958.x. [PubMed: 12702052].
6. Li H, Wang YJ, Tan K, Zeng L, Liu L, Liu FJ, et al. Prevalence and risk factors of fatty liver disease in Chengdu, Southwest China. *Hepatobiliary Pancreat Dis Int.* 2009;8(4):377-82. [PubMed: 19666406].
7. Mencin AA, Lavine JE. Nonalcoholic fatty liver disease in children. *Curr Opin Clin Nutr Metab Care.* 2011;14(2):151-7. doi: 10.1097/MCO.0b013e328342baec. [PubMed: 21178608].
8. McCullough AJ. Pathophysiology of nonalcoholic steatohepatitis. *J Clin Gastroenterol.* 2006;40 Suppl 1:S17-29. doi: 10.1097/01.mcg.0000168645.86658.22. [PubMed: 16540762].
9. Marchesini G, Marzocchi R, Agostini F, Bugianesi E. Nonalcoholic fatty liver disease and the metabolic syndrome. *Curr Opin Lipidol.* 2005;16(4):421-7. doi: 10.1097/01.mol.0000174153.53683.f2. [PubMed: 15990591].
10. Targher G, Arcaro G. Non-alcoholic fatty liver disease and increased risk of cardiovascular disease. *Atherosclerosis.* 2007;191(2):235-40. doi: 10.1016/j.atherosclerosis.2006.08.021. [PubMed: 16970951].
11. Patton HM, Sirlin C, Behling C, Middleton M, Schwimmer JB, Lavine JE. Pediatric nonalcoholic fatty liver disease: a critical appraisal of current data and implications for future research. *J Pediatr Gastroenterol Nutr.* 2006;43(4):413-27. doi: 10.1097/01.mpg.0000239995.58388.56. [PubMed: 17033514].
12. Dogru T, Genc H, Tapan S, Ercin CN, Ors F, Aslan F, et al. Elevated asymmetric dimethylarginine in plasma: an early marker for endothelial dysfunction in non-alcoholic fatty liver disease? *Diabetes Res Clin Pract.* 2012;96(1):47-52. doi: 10.1016/j.diabres.2011.11.022. [PubMed: 22189171].
13. Pinto HC, Baptista A, Camilo ME, Valente A, Saragoca A, de Moura MC. Nonalcoholic steatohepatitis. Clinicopathological comparison with alcoholic hepatitis in ambulatory and hospitalized patients. *Dig Dis Sci.* 1996;41(1):172-9. doi: 10.1007/BF02208601. [PubMed: 8565753].
14. Powell EE, Cooksley WG, Hanson R, Searle J, Halliday JW, Powell LW. The natural history of nonalcoholic steatohepatitis: a follow-up study of forty-two patients for up to 21 years. *Hepatology.* 1990;11(1):74-80. doi: 10.1002/hep.1840110114. [PubMed: 2295475].
15. Wanless IR, Lentz JS. Fatty liver hepatitis (steatohepatitis) and obesity: an autopsy study with analysis of risk factors. *Hepatology.* 1990;12(5):1106-10. doi: 10.1002/hep.1840120505. [PubMed: 2227807].
16. Assy N, Kaita K, Mymin D, Levy C, Rosser B, Minuk G. Fatty infiltration of liver in hyperlipidemic patients. *Dig Dis Sci.* 2000;45(10):1929-34. doi: 10.1023/A:1005661516165. [PubMed: 11117562].
17. Gilmore IT, Burroughs A, Murray-Lyon IM, Williams R, Jenkins D, Hopkins A. Indications, methods, and outcomes of percutaneous liver biopsy in England and Wales: an audit by the British Society of Gastroenterology and the Royal College of Physicians of London.

- Gut*. 1995;**36**(3):437-41. doi: [10.1136/gut.36.3.437](https://doi.org/10.1136/gut.36.3.437). [PubMed: [7698705](https://pubmed.ncbi.nlm.nih.gov/7698705/)]. [PubMed Central: [PMC1382461](https://pubmed.ncbi.nlm.nih.gov/PMC1382461/)].
18. Schwimmer JB. Definitive diagnosis and assessment of risk for nonalcoholic fatty liver disease in children and adolescents. *Semin Liver Dis*. 2007;**27**(3):312-8. doi: [10.1055/s-2007-985075](https://doi.org/10.1055/s-2007-985075). [PubMed: [17682977](https://pubmed.ncbi.nlm.nih.gov/17682977/)].
 19. Angulo P. Nonalcoholic fatty liver disease. *N Engl J Med*. 2002;**346**(16):1221-31. doi: [10.1056/NEJMra011775](https://doi.org/10.1056/NEJMra011775). [PubMed: [11961152](https://pubmed.ncbi.nlm.nih.gov/11961152/)].
 20. Loomba R, Sirlin CB, Schwimmer JB, Lavine JE. Advances in pediatric nonalcoholic fatty liver disease. *Hepatology*. 2009;**50**(4):1282-93. doi: [10.1002/hep.23119](https://doi.org/10.1002/hep.23119). [PubMed: [19637286](https://pubmed.ncbi.nlm.nih.gov/19637286/)]. [PubMed Central: [PMC2757471](https://pubmed.ncbi.nlm.nih.gov/PMC2757471/)].
 21. Kotronen A, Yki-Jarvinen H. Fatty liver: a novel component of the metabolic syndrome. *Arterioscler Thromb Vasc Biol*. 2008;**28**(1):27-38. doi: [10.1161/ATVBAHA.107.147538](https://doi.org/10.1161/ATVBAHA.107.147538). [PubMed: [17690317](https://pubmed.ncbi.nlm.nih.gov/17690317/)].
 22. Targher G, Bertolini L, Padovani R, Rodella S, Zoppini G, Zenari L, et al. Relations between carotid artery wall thickness and liver histology in subjects with nonalcoholic fatty liver disease. *Diabetes Care*. 2006;**29**(6):1325-30. doi: [10.2337/dc06-0135](https://doi.org/10.2337/dc06-0135). [PubMed: [16732016](https://pubmed.ncbi.nlm.nih.gov/16732016/)].
 23. Targher G, Bertolini L, Scala L, Zoppini G, Zenari L, Falezza G. Non-alcoholic hepatic steatosis and its relation to increased plasma biomarkers of inflammation and endothelial dysfunction in non-diabetic men. Role of visceral adipose tissue. *Diabet Med*. 2005;**22**(10):1354-8. doi: [10.1111/j.1464-5491.2005.01646.x](https://doi.org/10.1111/j.1464-5491.2005.01646.x). [PubMed: [16176196](https://pubmed.ncbi.nlm.nih.gov/16176196/)].
 24. Fracanzani AL, Burdick L, Raselli S, Pedotti P, Grigore L, Santorelli G, et al. Carotid artery intima-media thickness in nonalcoholic fatty liver disease. *Am J Med*. 2008;**121**(1):72-8. doi: [10.1016/j.amjmed.2007.08.041](https://doi.org/10.1016/j.amjmed.2007.08.041). [PubMed: [18187076](https://pubmed.ncbi.nlm.nih.gov/18187076/)].
 25. Targher G, Day CP, Bonora E. Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease. *N Engl J Med*. 2010;**363**(14):1341-50. doi: [10.1056/NEJMra092063](https://doi.org/10.1056/NEJMra092063). [PubMed: [20879883](https://pubmed.ncbi.nlm.nih.gov/20879883/)].
 26. Adams LA, Lymp JF, St Sauver J, Sanderson SO, Lindor KD, Feldstein A, et al. The natural history of nonalcoholic fatty liver disease: a population-based cohort study. *Gastroenterology*. 2005;**129**(1):113-21. doi: [10.1053/j.gastro.2005.04.014](https://doi.org/10.1053/j.gastro.2005.04.014). [PubMed: [16012941](https://pubmed.ncbi.nlm.nih.gov/16012941/)].
 27. Ekstedt M, Franzen LE, Mathiesen UL, Thorelius L, Holmqvist M, Bodemar G, et al. Long-term follow-up of patients with NAFLD and elevated liver enzymes. *Hepatology*. 2006;**44**(4):865-73. doi: [10.1002/hep.21327](https://doi.org/10.1002/hep.21327). [PubMed: [17006923](https://pubmed.ncbi.nlm.nih.gov/17006923/)].
 28. Rafiq N, Bai C, Fang Y, Srishord M, McCullough A, Gramlich T, et al. Long-term follow-up of patients with nonalcoholic fatty liver. *Clin Gastroenterol Hepatol*. 2009;**7**(2):234-8. doi: [10.1016/j.cgh.2008.11.005](https://doi.org/10.1016/j.cgh.2008.11.005). [PubMed: [19049831](https://pubmed.ncbi.nlm.nih.gov/19049831/)].
 29. Soderberg C, Stal P, Askling J, Glaumann H, Lindberg G, Marmur J, et al. Decreased survival of subjects with elevated liver function tests during a 28-year follow-up. *Hepatology*. 2010;**51**(2):595-602. doi: [10.1002/hep.23314](https://doi.org/10.1002/hep.23314). [PubMed: [20014114](https://pubmed.ncbi.nlm.nih.gov/20014114/)].
 30. Ramilli S, Pretolani S, Muscari A, Pacelli B, Arienti V. Carotid lesions in outpatients with nonalcoholic fatty liver disease. *World J Gastroenterol*. 2009;**15**(38):4770-4. doi: [10.3748/wjg.15.4770](https://doi.org/10.3748/wjg.15.4770). [PubMed: [19824109](https://pubmed.ncbi.nlm.nih.gov/19824109/)]. [PubMed Central: [PMC2761553](https://pubmed.ncbi.nlm.nih.gov/PMC2761553/)].
 31. Chen CH, Nien CK, Yang CC, Yeh YH. Association between non-alcoholic fatty liver disease and coronary artery calcification. *Dig Dis Sci*. 2010;**55**(6):1752-60. doi: [10.1007/s10620-009-0935-9](https://doi.org/10.1007/s10620-009-0935-9). [PubMed: [19688595](https://pubmed.ncbi.nlm.nih.gov/19688595/)].
 32. Taheri MS, Haghghatkhah H, Tash MH, Bakhshian R, Shakiba M, Jalali A. [The prevalence of carotid artery disease in candidates of coronary artery bypass graft]. *Iran J Radiol*. 2006;**3**(4). Persian.
 33. Antonini-Canterin F, Leiballi E, Capanna M, Burelli C, Cassin M, Macor F, et al. Association between carotid and coronary artery disease in patients with aortic valve stenosis: An angiographic study. *Angiology*. 2009;**60**(5):596-600. doi: [10.1177/0003319708327646](https://doi.org/10.1177/0003319708327646). [PubMed: [19049997](https://pubmed.ncbi.nlm.nih.gov/19049997/)].
 34. Mortaz Hejri S, Mostafazadeh Davani B, Sahraini MA. Carotid endarterectomy for carotid stenosis in patients selected for coronary artery bypass graft surgery. *Cochrane Database Syst Rev*. 2009;(4). CD006074. doi: [10.1002/14651858.CD006074.pub2](https://doi.org/10.1002/14651858.CD006074.pub2). [PubMed: [19821353](https://pubmed.ncbi.nlm.nih.gov/19821353/)].
 35. Shirani S, Boroumand MA, Abbasi SH, Maghsoodi N, Shakiba M, Karimi A, et al. Preoperative carotid artery screening in patients undergoing coronary artery bypass graft surgery. *Arch Med Res*. 2006;**37**(8):987-90. doi: [10.1016/j.arcmed.2006.06.001](https://doi.org/10.1016/j.arcmed.2006.06.001). [PubMed: [17045115](https://pubmed.ncbi.nlm.nih.gov/17045115/)].
 36. Ascher E, Hingorani A, Yorkovich W, Ramsey PJ, Salles-Cunha S. Routine preoperative carotid duplex scanning in patients undergoing open heart surgery: is it worthwhile? *Ann Vasc Surg*. 2001;**15**(6):669-78. doi: [10.1007/s10016-001-0088-6](https://doi.org/10.1007/s10016-001-0088-6). [PubMed: [11769149](https://pubmed.ncbi.nlm.nih.gov/11769149/)].
 37. Kim HC, Kim DJ, Huh KB. Association between nonalcoholic fatty liver disease and carotid intima-media thickness according to the presence of metabolic syndrome. *Atherosclerosis*. 2009;**204**(2):521-5. doi: [10.1016/j.atherosclerosis.2008.09.012](https://doi.org/10.1016/j.atherosclerosis.2008.09.012). [PubMed: [18947828](https://pubmed.ncbi.nlm.nih.gov/18947828/)].
 38. O'Leary DH, Polak JF, Kronmal RA, Manolio TA, Burke GL, Wolfson SK, Jr. Carotid-artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults. Cardiovascular Health Study Collaborative Research Group. *N Engl J Med*. 1999;**340**(1):14-22. doi: [10.1056/NEJM199901073400103](https://doi.org/10.1056/NEJM199901073400103). [PubMed: [9878640](https://pubmed.ncbi.nlm.nih.gov/9878640/)].
 39. Bots ML, Hoes AW, Koudstaal PJ, Hofman A, Grobbee DE. Common carotid intima-media thickness and risk of stroke and myocardial infarction: the Rotterdam Study. *Circulation*. 1997;**96**(5):1432-7. doi: [10.1161/01.CIR.96.5.1432](https://doi.org/10.1161/01.CIR.96.5.1432). [PubMed: [9315528](https://pubmed.ncbi.nlm.nih.gov/9315528/)].
 40. Lorenz MW, Markus HS, Bots ML, Rosvall M, Sitzer M. Prediction of clinical cardiovascular events with carotid intima-media thickness: A systematic review and meta-analysis. *Circulation*. 2007;**115**(4):459-67. doi: [10.1161/CIRCULATIONAHA.106.628875](https://doi.org/10.1161/CIRCULATIONAHA.106.628875). [PubMed: [17242284](https://pubmed.ncbi.nlm.nih.gov/17242284/)].
 41. Volzke H, Robinson DM, Kleine V, Deutscher R, Hoffmann W, Lude-mann J, et al. Hepatic steatosis is associated with an increased risk of carotid atherosclerosis. *World J Gastroenterol*. 2005;**11**(2):1848-53. doi: [10.3748/wjg.v11.i2.1848](https://doi.org/10.3748/wjg.v11.i2.1848). [PubMed: [15793879](https://pubmed.ncbi.nlm.nih.gov/15793879/)]. [PubMed Central: [PMC4305889](https://pubmed.ncbi.nlm.nih.gov/PMC4305889/)].
 42. Jepsen P, Vilstrup H, Mellekmjaer L, Thulstrup AM, Olsen JH, Baron JA, et al. Prognosis of patients with a diagnosis of fatty liver—a registry-based cohort study. *Hepatogastroenterology*. 2003;**50**(54):2101-4. [PubMed: [14696473](https://pubmed.ncbi.nlm.nih.gov/14696473/)].
 43. Day CP. Natural history of NAFLD: remarkably benign in the absence of cirrhosis. *Gastroenterology*. 2005;**129**(1):375-8. doi: [10.1053/j.gastro.2005.05.041](https://doi.org/10.1053/j.gastro.2005.05.041). [PubMed: [16012969](https://pubmed.ncbi.nlm.nih.gov/16012969/)].
 44. Valentina VN, Marijan B, Chedo D, Branka K. Subclinical hypothyroidism and risk to carotid atherosclerosis. *Arq Bras Endocrinol Metabol*. 2011;**55**(7):475-80. doi: [10.1590/S0004-27302011000700007](https://doi.org/10.1590/S0004-27302011000700007). [PubMed: [22147096](https://pubmed.ncbi.nlm.nih.gov/22147096/)].
 45. Chiche F, Jublanc C, Coudert M, Carreau V, Kahn JF, Bruckert E. Hypothyroidism is not associated with increased carotid atherosclerosis when cardiovascular risk factors are accounted for in hyperlipidemic patients. *Atherosclerosis*. 2009;**203**(1):269-76. doi: [10.1016/j.atherosclerosis.2008.06.011](https://doi.org/10.1016/j.atherosclerosis.2008.06.011). [PubMed: [18649881](https://pubmed.ncbi.nlm.nih.gov/18649881/)].
 46. Caldwell SH, Crespo DM. The spectrum expanded: cryptogenic cirrhosis and the natural history of non-alcoholic fatty liver disease. *J Hepatol*. 2004;**40**(4):578-84. doi: [10.1016/j.jhep.2004.02.013](https://doi.org/10.1016/j.jhep.2004.02.013). [PubMed: [15030972](https://pubmed.ncbi.nlm.nih.gov/15030972/)].
 47. Fahimi F, Shafiee K, Ahmadi J, Mehrabian M, Pezeshki E, Dehghani A. [Relationship between non alcoholic fatty liver disease with hemodynamic indexes of intracranial cerebral vessels in transcranial doppler ultrasound]. *J Rafsanjan Univ Med Sci Health Serv*. 2013;**11**(6):567-74. Persian.
 48. Ruderman N, Chisholm D, Pi-Sunyer X, Schneider S. The metabolically obese, normal-weight individual revisited. *Diabetes*. 1998;**47**(5):699-713. doi: [10.2337/diabetes.47.5.699](https://doi.org/10.2337/diabetes.47.5.699). [PubMed: [9588440](https://pubmed.ncbi.nlm.nih.gov/9588440/)].

49. Bahrami H, Daryani NE, Mirmomen S, Kamangar F, Haghpanah B, Djalili M. Clinical and histological features of nonalcoholic steatohepatitis in Iranian patients. *BMC Gastroenterol.* 2003;**3**:27. doi: [10.1186/1471-230X-3-27](https://doi.org/10.1186/1471-230X-3-27). [PubMed: [14561231](https://pubmed.ncbi.nlm.nih.gov/14561231/)]. [PubMed Central: [PMC270051](https://pubmed.ncbi.nlm.nih.gov/PMC270051/)].
50. Tarantino G, Finelli C, Colao A, Capone D, Tarantino M, Grimaldi E, et al. Are hepatic steatosis and carotid intima media thickness associated in obese patients with normal or slightly elevated gamma-glutamyl-transferase? *J Transl Med.* 2012;**10**:50. doi: [10.1186/1479-5876-10-50](https://doi.org/10.1186/1479-5876-10-50). [PubMed: [22424154](https://pubmed.ncbi.nlm.nih.gov/22424154/)]. [PubMed Central: [PMC3342159](https://pubmed.ncbi.nlm.nih.gov/PMC3342159/)].
51. Sert A, Aypar E, Pirgon O, Yilmaz H, Odabas D, Tolu I. Left ventricular function by echocardiography, tissue Doppler imaging, and carotid intima-media thickness in obese adolescents with non-alcoholic fatty liver disease. *Am J Cardiol.* 2013;**112**(3):436-43. doi: [10.1016/j.amjcard.2013.03.056](https://doi.org/10.1016/j.amjcard.2013.03.056). [PubMed: [23642511](https://pubmed.ncbi.nlm.nih.gov/23642511/)].
52. Jarvisalo MJ, Jartti L, Nanto-Salonen K, Irjala K, Ronnema T, Hartiala J, et al. Increased aortic intima-media thickness: a marker of preclinical atherosclerosis in high-risk children. *Circulation.* 2001;**104**(24):2943-7. doi: [10.1161/hc4901.100522](https://doi.org/10.1161/hc4901.100522). [PubMed: [11739310](https://pubmed.ncbi.nlm.nih.gov/11739310/)].
53. Manco M, Bedogni G, Monti L, Morino G, Natali G, Nobili V. Intima-media thickness and liver histology in obese children and adolescents with non-alcoholic fatty liver disease. *Atherosclerosis.* 2010;**209**(2):463-8. doi: [10.1016/j.atherosclerosis.2009.10.014](https://doi.org/10.1016/j.atherosclerosis.2009.10.014). [PubMed: [19897197](https://pubmed.ncbi.nlm.nih.gov/19897197/)].
54. Berenson GS, Srinivasan SR, Bao W, Newman WP, Tracy RE, Wattigney WA. Association between multiple cardiovascular risk factors and atherosclerosis in children and young adults. The Bogalusa Heart Study. *N Engl J Med.* 1998;**338**(23):1650-6. doi: [10.1056/NEJM199806043382302](https://doi.org/10.1056/NEJM199806043382302). [PubMed: [9614255](https://pubmed.ncbi.nlm.nih.gov/9614255/)].
55. Durand DJ, Perler BA, Roseborough GS, Grega MA, Borowicz LM, Jr, Baumgartner WA, et al. Mandatory versus selective preoperative carotid screening: a retrospective analysis. *Ann Thorac Surg.* 2004;**78**(1):159-66. discussion 159-66. doi: [10.1016/j.athoracsur.2004.02.024](https://doi.org/10.1016/j.athoracsur.2004.02.024). [PubMed: [15223422](https://pubmed.ncbi.nlm.nih.gov/15223422/)].
56. Diehl AM, Goodman Z, Ishak KG. Alcoholic liver disease in nonalcoholics. A clinical and histologic comparison with alcohol-induced liver injury. *Gastroenterology.* 1988;**95**(4):1056-62. doi: [10.1016/0016-5085\(88\)90183-7](https://doi.org/10.1016/0016-5085(88)90183-7). [PubMed: [3410220](https://pubmed.ncbi.nlm.nih.gov/3410220/)].
57. Caserta CA, Pendino GM, Amante A, Vacalebre C, Fiorillo MT, Surace P, et al. Cardiovascular risk factors, nonalcoholic fatty liver disease, and carotid artery intima-media thickness in an adolescent population in southern Italy. *Am J Epidemiol.* 2010;**171**(11):195-202. doi: [10.1093/aje/kwq073](https://doi.org/10.1093/aje/kwq073). [PubMed: [20457571](https://pubmed.ncbi.nlm.nih.gov/20457571/)].
58. Roitberg GE, Sharkhun OO, Ushakova TI. [Non-alcoholic fatty liver disease as an atherosclerosis risk factor]. *Eksp Klin Gastroenterol.* 2010;**(7)**:20-4. [PubMed: [21033079](https://pubmed.ncbi.nlm.nih.gov/21033079/)].
59. Vlachopoulos C, Manesis E, Baou K, Papatheodoridis G, Koskinas J, Tiniakos D, et al. Increased arterial stiffness and impaired endothelial function in nonalcoholic fatty liver disease: A pilot study. *Am J Hypertens.* 2010;**23**(11):1183-9. doi: [10.1038/ajh.2010.144](https://doi.org/10.1038/ajh.2010.144). [PubMed: [20634799](https://pubmed.ncbi.nlm.nih.gov/20634799/)].
60. Karakurt F, Carlioglu A, Koktener A, Ozbek M, Kaya A, Uyar ME, et al. Relationship between cerebral arterial pulsatility and carotid intima media thickness in diabetic and non-diabetic patients with non-alcoholic fatty liver disease. *J Endocrinol Invest.* 2009;**32**(1):63-8. doi: [10.1007/BF03345681](https://doi.org/10.1007/BF03345681). [PubMed: [19337018](https://pubmed.ncbi.nlm.nih.gov/19337018/)].
61. Sookoian S, Pirola CJ. Non-alcoholic fatty liver disease is strongly associated with carotid atherosclerosis: A systematic review. *J Hepatol.* 2008;**49**(4):600-7. doi: [10.1016/j.jhep.2008.06.012](https://doi.org/10.1016/j.jhep.2008.06.012). [PubMed: [18672311](https://pubmed.ncbi.nlm.nih.gov/18672311/)].
62. Akin L, Kurtoglu S, Yikilmaz A, Kendirci M, Elmali F, Mazicioglu M. Fatty liver is a good indicator of subclinical atherosclerosis risk in obese children and adolescents regardless of liver enzyme elevation. *Acta Paediatr.* 2013;**102**(3):e107-13. doi: [10.1111/apa.12099](https://doi.org/10.1111/apa.12099). [PubMed: [23190373](https://pubmed.ncbi.nlm.nih.gov/23190373/)].
63. Chavez-Tapia NC, Lizardi-Cervera J, Perez-Bautista O, Ramos-Ostos MH, Uribe M. Smoking is not associated with nonalcoholic fatty liver disease. *World J Gastroenterol.* 2006;**12**(32):5196-200. doi: [10.3748/wjg.v12.i32.5196](https://doi.org/10.3748/wjg.v12.i32.5196). [PubMed: [16937532](https://pubmed.ncbi.nlm.nih.gov/16937532/)]. [PubMed Central: [PMC4088019](https://pubmed.ncbi.nlm.nih.gov/PMC4088019/)].